EPICS: Global Perspectives in CRC in 2022 and Beyond

Latest therapeutic developments in GI cancer treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

March 16, 2022
Purchase Report

FACULTY CHAIR

Alan P. Venook, MD

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Faculty Members

Al Bowen Benson, MD
Northwestern Medicine, Chicago, IL, USA

Aparna Parikh, MD
Mass General Cancer Center, Boston, MA, USA

Pashtoon M. Kasi, MD
Weill Cornell Medicine, New York, NY, USA

Eric Van Cutsem, MD, PhD
University Hospitals Gasthuisberg, Leuven, Belgium

Dirk Arnold, MD, PhD
University of Hamburg, Germany

Sample Report

Start discovering the insights

View Report

REPORT TOPICS INCLUDE

  • Current Treatment Paradigms for Early-Stage CRC (MSS/pMMR)
  • Current Treatment Paradigms for Metastatic CRC
  • The Evolving Role of Immunotherapy in CRC
  • Currently Available Targeted Therapies for CRC
  • Emerging Therapies and Novel Investigational Approaches for CRC
  • Current and Evolving Biomarkers in CRC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.